Abstract

Fluorometric quantification of biological molecules is a key feature used in many biosensing studies. Fluorescence resonance energy transfer (FRET) using highly fluorescent quantum dots offers highly sensitive detection of the in-proximity wide variety of analyst molecules. In this contribution, we report the use of carbon quantum dots (CDs) for the ultrasensitive optical biosensing of cancer antigen 125 (CA-125) in the early malignant stage. This approach is based on monitoring the quenching of CDs luminescence at 535 nm by CA-125 after excitation at 425 nm and pH 10. The calibration of this method was performed in the concentration range of CA-125 from 0.01 to 129 U ml−1 (R2 = 0.99) with a detection limit of 0.66 U ml−1, which matches remarkably with the standard chemiluminometric method in control and real patient samples. The sensing mechanism for cancer antigen 125 assessment was discussed on the basis of fluorescence quenching of CDs and time-resolved photoluminescence spectroscopy. The current method is easy, sensitive, cost-effective and provides a wide range of validity, which helps in overcoming the limitations of high cost and time consumption exhibited by many other traditional clinical assays for CA-125 quantification.

Highlights

  • Tumor antigen 125 (CA-125) is a surface antigen associated with non-mucinous epithelial ovarian cancer.[1]

  • The CA125 test is one of the blood tests that can be ordered if ovarian cancer is suspected, as cancer antigen 125 (CA-125) levels can increase in benign conditions such as diverticulitis, endometriosis, cirrhosis of the liver, pregnancy, and uterine broids.[6]

  • We have developed a uorescence quenching method for the determination of CA-125, which offers an excellent approach to create high-quality biomarkers for early detection of ovarian cancer

Read more

Summary

Introduction

Tumor antigen 125 (CA-125) is a surface antigen associated with non-mucinous epithelial ovarian cancer.[1]. Early-stage ovarian cancer diagnosis, in which the disease is limited to the ovaries, is more likely to be treatable. This can be done by monitoring the concentration of CA-125

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call